caffeine has been researched along with Retrolental Fibroplasia in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "To determine whether prophylactic caffeine and ibuprofen, which have been shown to have vascular endothelial growth factor-modulating properties in other contexts, have a detectable effect on the incidence of severe retinopathy of prematurity (ROP) when administered in extremely low birth weight infants during the first 48 hours of life." | 8.02 | The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2021) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 7.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants." | 4.98 | Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018) |
| " Despite aggressive respiratory support including mechanical ventilation, continuous positive airway pressure, oxygen and caffeine therapy to reduce apnea and accompanying intermittent hypoxemia, the incidence of intermittent hypoxemia events continues to increase during the first few months of life." | 4.93 | Cardiorespiratory events in preterm infants: interventions and consequences. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016) |
| "To determine whether prophylactic caffeine and ibuprofen, which have been shown to have vascular endothelial growth factor-modulating properties in other contexts, have a detectable effect on the incidence of severe retinopathy of prematurity (ROP) when administered in extremely low birth weight infants during the first 48 hours of life." | 4.02 | The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2021) |
| "Caffeine or ketorolac decrease the risk of retinopathy of prematurity and may act synergistically to improve beneficial effect." | 3.83 | Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy. ( Ahmad, T; Aranda, JV; Beharry, KD; Bronshtein, V; Cai, CL; Lazzaro, DR; Sadeh, J; Valencia, GB, 2016) |
| " Caffeine is frequently used for apnea of prematurity." | 3.83 | Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine? ( Ahmad, A; Klein, B; Mondal, T, 2016) |
| "Although a causal relationship was not identified, the use of the autonomic agents caffeine and dopamine was associated with the development and severity of retinopathy of prematurity in this cohort." | 3.80 | Evaluating the association of autonomic drug use to the development and severity of retinopathy of prematurity. ( Coats, DK; Hussein, MA; Khan, H; Kong, L; O'Brian, SE; Paysse, EA; Steinkuller, PG, 2014) |
| "When asked to address the above question, findings that appeared to be among the most relevant included (1) interventions in the delivery room directed at supporting the physiological transition from intrauterine to extrauterine life rather than actively intervening in it; (2) recent data suggesting that keeping extremely low-gestational age neonates at a pulse oximeter saturation (SpO(2)) of 91-95% would increase their chances of survival compared with aiming for lower SpO(2) values; (3) using caffeine citrate in infants <1250 g with apnoea of prematurity improves neurodevelopmental outcome; (4) injecting antivascular epithelial growth factor into the vitreous seems to be an effective treatment for retinopathy of prematurity and (5) moderate hypothermia for perinatal hypoxic-ischaemic encephalopathy increases the likelihood of survival without neurological impairment." | 3.79 | What are the main research findings during the last 5 years that have changed my approach to clinical practice? ( Poets, CF, 2013) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 3.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt-Mehta, V | 1 |
| Schumacher, RE | 1 |
| Parikh, NA | 1 |
| Sharma, P | 1 |
| He, L | 1 |
| Li, H | 2 |
| Altaye, M | 1 |
| Priyanka Illapani, VS | 1 |
| Zhang, S | 2 |
| Zhou, R | 2 |
| Li, B | 1 |
| Wang, Y | 1 |
| Gu, X | 1 |
| Tang, L | 1 |
| Wang, C | 1 |
| Zhong, D | 1 |
| Ge, Y | 1 |
| Huo, Y | 2 |
| Lin, J | 2 |
| Liu, XL | 1 |
| Chen, JF | 2 |
| Dobson, NR | 1 |
| Hunt, CE | 1 |
| Hussein, MA | 1 |
| Coats, DK | 1 |
| Khan, H | 1 |
| Paysse, EA | 1 |
| Steinkuller, PG | 1 |
| Kong, L | 1 |
| O'Brian, SE | 1 |
| Di Fiore, JM | 1 |
| Poets, CF | 2 |
| Gauda, E | 1 |
| Martin, RJ | 1 |
| MacFarlane, P | 1 |
| Beharry, KD | 2 |
| Valencia, GB | 2 |
| Lazzaro, DR | 2 |
| Aranda, JV | 3 |
| Cai, CL | 1 |
| Ahmad, T | 1 |
| Bronshtein, V | 1 |
| Sadeh, J | 1 |
| Ahmad, A | 1 |
| Mondal, T | 1 |
| Klein, B | 1 |
| Lin, Z | 1 |
| Cai, X | 1 |
| Liu, X | 1 |
| Schmidt, B | 1 |
| Roberts, RS | 1 |
| Davis, P | 1 |
| Doyle, LW | 1 |
| Barrington, KJ | 1 |
| Ohlsson, A | 1 |
| Solimano, A | 1 |
| Tin, W | 1 |
| Stevenson, DK | 1 |
| Gunn, TR | 1 |
| Metrakos, K | 1 |
| Riley, P | 1 |
| Willis, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Prediction of Cognitive and Motor Deficits Using Advanced MRI in Very Preterm Infants[NCT03345069] | 393 participants (Actual) | Observational | 2016-09-16 | Active, not recruiting | |||
| Apneic Oxygenation to Prevent Oxygen Desaturation During Intubation in the NICU[NCT05451953] | 110 participants (Anticipated) | Interventional | 2022-07-21 | Recruiting | |||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for caffeine and Retrolental Fibroplasia
| Article | Year |
|---|---|
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot | 2018 |
Cardiorespiratory events in preterm infants: interventions and consequences.
Topics: Animals; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Continuous Positive Airway | 2016 |
Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.
Topics: Antioxidants; Caffeine; Combined Modality Therapy; Disease Progression; Early Medical Intervention; | 2016 |
Adenosine receptors and caffeine in retinopathy of prematurity.
Topics: Animals; Caffeine; Disease Models, Animal; Humans; Infant, Newborn; Oxygen; Purinergic P1 Receptor A | 2017 |
1 trial available for caffeine and Retrolental Fibroplasia
| Article | Year |
|---|---|
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
9 other studies available for caffeine and Retrolental Fibroplasia
| Article | Year |
|---|---|
The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity.
Topics: Birth Weight; Caffeine; Gestational Age; Humans; Ibuprofen; Infant, Newborn; Infant, Very Low Birth | 2021 |
Perinatal Risk and Protective Factors in the Development of Diffuse White Matter Abnormality on Term-Equivalent Age Magnetic Resonance Imaging in Infants Born Very Preterm.
Topics: Bronchopulmonary Dysplasia; Caffeine; Cohort Studies; Dexamethasone; Female; Gestational Age; Glucoc | 2021 |
Caffeine preferentially protects against oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Caffeine; Endothelium, Vascular; Gene Expression Regulation; Mice; Mice, | 2017 |
Evaluating the association of autonomic drug use to the development and severity of retinopathy of prematurity.
Topics: Autonomic Nervous System; Caffeine; Central Nervous System Stimulants; Dopamine; Female; Gestational | 2014 |
Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Apyrase; Arteries; Body Weight; | 2016 |
Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine?
Topics: Apnea; Atrial Premature Complexes; Bradycardia; Caffeine; Central Nervous System Stimulants; Cyclope | 2016 |
What are the main research findings during the last 5 years that have changed my approach to clinical practice?
Topics: Apnea; Caffeine; Humans; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Infant, Extremely Premature; | 2013 |
On the caffeination of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2007 |
Sequelae of caffeine treatment in preterm infants with apnea.
Topics: Apnea; Caffeine; Child Development; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Inf | 1979 |